ELAB shares are trading higher after its subsidiary, NorthStrive Biosciences, announced a licensing agreement amendment with MOA Life Plus for dual myostatin assets, aligning development milestones for its EL-22 and EL-32 programs.

Quantum Biopharma shares are trading higher after the company reported robust 2025 financial results, highlighting a strong cash position, reduced liabilities, and advancements in multiple sclerosis and alcohol metabolism drug candidates.

Oxford Industries shares are trading higher after the company initiated fiscal 2026 guidance reflecting improved profitability, driven by momentum at Tommy Bahama. The guidance includes anticipated revenues of $1.475 billion to $1.530 billion and a GAAP EPS of $1.83 to $2.43.

VirTra shares are trading lower after the company reported a 15% decrease in annual revenue and a 45% drop in adjusted EBITDA for 2025, attributed to delays in government funding and customer purchasing cycles.

AmpliTech Group shares are trading lower after the company reported fiscal year results that highlighted significant margin compression despite a 165% increase in revenue, driven by strategic investments in 5G market expansion.

Iridex shares are trading lower after the company reported increasing manufacturing costs and tariff-related challenges impacting gross margins, despite revenue growth in Q4 2025.

Argan shares are trading higher after the company reported record fourth quarter and fiscal year 2026 financial results, with significant increases in revenue, net income, and a robust project backlog exceeding $2.9 billion.

Nortech Systems shares are trading higher after the company reported a significant increase in net income and improved EBITDA for Q4 2025 compared to the previous year.

Glucotrack shares are trading higher after the company announced plans to submit an Investigational Device Exemption (IDE) to the FDA for its novel continuous blood glucose monitoring technology, following successful clinical trials in Brazil and Australia.

Huize Holding shares are trading lower, as investors react negatively despite the company achieving record-breaking insurance premiums and robust revenue growth in 2025, likely due to increased operating costs and reduced net profit in the latter half of the year.

ADMA Biologics shares are trading higher after the company refuted misleading allegations, confirming real and growing demand for ASCENIV and highlighting record high utilization.

Zenas BioPharma shares are trading lower after the company announced the pricing of public offerings for $200 million in convertible senior notes and 5 million shares of common stock, diluting existing shares.

Lantern Pharma shares are trading higher after the FDA cleared the Investigational New Drug application for STAR-001, allowing a Phase 1 pediatric clinical trial to commence.

Gain Therapeutics shares are trading lower after the company reported a net loss of $20.2 million for the year ended December 31, 2025, despite a decrease in operating expenses.

MetaVia shares are trading higher after the company announced significant progress in its cardiometabolic portfolio, highlighted by positive Phase 1 data for its lead asset DA-1726 and a strengthened cash position following a $9.3 million public offering.

Genenta shares are trading higher after announcing a binding offer to acquire a controlling stake in Sòphia High Tech, boosting its position in aerospace and defense manufacturing.

Veritone shares are trading lower following a report of significant financial challenges, including a net loss ranging from $110.5 million to $98.6 million for 2025. The company's profitability is overshadowed by its extensive efforts to reduce debt, which included a cash expense of approximately $13.0 million for accelerated debt discount charges and the reduction of debt by over $77 million. Despite pioneering AI partnerships and a solid revenue pipeline, Veritone's sustainability remains questioned due to these financial hurdles.

Cognition Therapeutics (CGTX) shares are trading lower after the company reported a net loss of $23.5 million for 2025, despite reduced R&D and administrative expenses compared to 2024.

Unity shares are trading higher after the company reported preliminary Q1 2026 revenue and Adjusted EBITDA above guidance, driven by strong growth in Unity Vector and Create segments.

X Financial shares are trading lower after the company reported disappointing Q4 financial results, with net income decreasing by 85.2% year-over-year due to higher provisioning and lower loan facilitation revenue.